Medfinder
Locates medications in stock near you, including specialty drugs and those in shortage.
Website: https://www.medfinder.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | Medfinder (formerly Insito Medfinder) |
| Tagline | Locates medications in stock near you, including specialty drugs and those in shortage |
| Headquarters | Boston, United States |
| Stage | Seed |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Parth Shah (Co-Founder, CTO), Dagget (Co-Founder) |
| Headcount Band | 1-10 employees [Wellfound] |
Links
PUBLIC
- Website: https://www.medfinder.com
- LinkedIn: https://www.linkedin.com/company/trymedfinder
- Wellfound: https://wellfound.com/company/trymedfinder
- Crunchbase: https://www.crunchbase.com/organization/medfinder
- PitchBook: https://pitchbook.com/profiles/company/545919-85
- Trustpilot: https://www.trustpilot.com/review/www.medfinder.com
Executive Summary
PUBLIC
Medfinder is a Boston-based healthtech company that helps patients and prescribers locate specific medications in stock at nearby pharmacies, with a particular focus on specialty drugs and products affected by shortages such as Adderall and Ozempic [Quartz]. The company, originally branded Insito Medfinder, was launched by Parth Shah and a co-founder identified publicly as Dagget, and has rebranded under the shorter Medfinder name [Medfinder; Pain News Network, August 2024]. The product is sold to consumers as one-time search packages with no subscription, and to providers through a separate workflow-friendly tool that lets clinical staff route prescriptions to pharmacies confirmed to have stock [Medfinder]. The operating model, as reported by Quartz, combines a software front end with a human verification layer staffed by overseas freelancers who call and confirm pharmacy inventory in real time [Quartz]. Funding details are not disclosed in Crunchbase or PitchBook beyond a seed-stage classification, and the company is listed as having between one and ten employees on Wellfound, with at least one Boston-based engineering role posted at $125k to $155k plus 0.25 to 1.0 percent equity [Wellfound; Crunchbase]. Public customer reviews on Trustpilot describe successful fills for hard-to-find prescriptions and direct coordination with prescribers, suggesting early product-market fit in a narrow but acute use case [Trustpilot]. Over the next 12 to 18 months, the questions worth tracking are whether the provider-facing product can convert into recurring B2B revenue, whether the human-in-the-loop verification model can scale without margin compression, and whether persistent shortages of stimulants and GLP-1s continue to drive consumer demand.
Data Accuracy: GREEN -- Confirmed by Medfinder, Quartz, Wellfound, Crunchbase, and Pain News Network.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B2C (consumer search packages plus provider tooling) |
| Industry / Vertical | Healthtech, medication access |
| Technology Type | Software with human-verified data layer |
| Geography | North America (US-focused, Boston HQ) |
| Growth Profile | Venture Scale |
| Founding Team | Two co-founders, technical lead identified |
Company Overview
PUBLIC
Medfinder began life as Insito Medfinder, a name still attached to the company's PitchBook profile, and rebranded to the shorter Medfinder mark in a transition the company described publicly on its blog as part of a broader effort to clarify positioning [Medfinder; PitchBook]. The company is headquartered in Boston and was launched by Parth Shah and a co-founder publicly referenced as Dagget, according to coverage by Pain News Network in August 2024 [Pain News Network, August 2024]. Parth Shah is listed on LinkedIn and RocketReach as Co-Founder and CTO, based in Gainesville, Florida, with prior roles at Abilitare and the University of Florida between 2019 and 2021 [LinkedIn; RocketReach].
The stated mission, drawn from the company's About page, is to reduce the time Americans spend on healthcare administration. Medfinder's own framing cites a figure of "almost 100 hours every year" spent by the average American navigating healthcare, a number the company uses to motivate the product but does not source to a third-party study [Medfinder]. The earliest external press capture of the company is the August 2024 Pain News Network feature, followed by Quartz coverage that detailed the operational model of using overseas freelancers to verify pharmacy inventory [Pain News Network, August 2024; Quartz]. The Crunchbase profile classifies Medfinder as enabling consumers to order medicines online and access offers tied to their condition, although the live website emphasizes search and verification rather than direct fulfillment [Crunchbase].
Milestones that can be confirmed from public sources are limited: the launch noted in mid-2024 press, the rebrand from Insito Medfinder to Medfinder, the publication of a provider-facing product page, and ongoing blog activity through 2026 covering specific drug shortages including Adderall IR [Medfinder; Pain News Network, August 2024]. No legal entity filing has been verified in this research pass.
Data Accuracy: YELLOW -- Crunchbase and Pain News Network corroborate launch and founders; legal entity, exact founding year, and incorporation state are not confirmed in the captured sources.
Product and Technology
MIXED
Medfinder operates two surfaces. The consumer product, accessible at medfinder.com, lets a patient enter a medication name and location and receive confirmation of which nearby pharmacies have the prescription in stock, including specialty drugs, rare disease treatments, limited-distribution products, and medications in active shortage [PUBLIC] [Medfinder]. Pricing is structured as one-time fees for single or multi-search packages with no subscription requirement, a model the company highlights on its pricing page as a deliberate alternative to recurring billing [PUBLIC] [Medfinder]. The provider product, marketed at medfinder.com/providers, is positioned as a way for clinical staff to identify in-stock pharmacies for their patients without changing existing e-prescribing workflows; the page invites clinicians to schedule a demo rather than self-serve sign-up, suggesting a sales-led motion for the B2B side [PUBLIC] [Medfinder].
The most distinctive aspect of the technology stack is what sits behind the search box. Quartz reported that Medfinder "outsources the detective work of finding which pharmacies have these medicines in stock to freelancers abroad" [PUBLIC] [Quartz]. In other words, the in-stock determination is not derived from a real-time pharmacy inventory API (no such universal API exists in the US retail pharmacy market) but from human callers verifying availability on demand. This is a meaningful design choice: it sidesteps the integration burden that would otherwise gate a product like this, and it lets Medfinder serve the long tail of independent and chain pharmacies uniformly, but it ties unit economics to labor cost and call success rates rather than to software margins [MIXED] [Quartz; Medfinder].
The content layer is a sustained blog operation covering specific drugs and shortages, including a 2026 update on the Adderall IR shortage and instructional posts on checking pharmacy stock for medications such as Azstarys and Clonazepam [PUBLIC] [Medfinder]. These posts both rank for high-intent SEO queries and openly compare Medfinder's approach to alternatives such as GoodRx pricing pages, which the blog acknowledges can serve as an indirect signal of stock [PUBLIC] [Medfinder]. A privacy policy is published, which is necessary table stakes given that the product handles prescription-level information, although a formal HIPAA covered-entity or business-associate posture is not stated in the captured sources [PUBLIC] [Medfinder].
Data Accuracy: GREEN -- Product surfaces and pricing confirmed by Medfinder's own site; operational model corroborated by Quartz.
Market Research and Opportunity
PUBLIC
Drug shortages in the United States have moved from a clinical inconvenience to a recurring policy concern, and that backdrop is the single most important tailwind for any business built around medication availability. The American Society of Health-System Pharmacists has tracked persistent active shortages across stimulants, GLP-1 receptor agonists, oncology infusions, and ADHD medications throughout 2023 and 2024, with the FDA's own drug shortage database confirming Adderall and semaglutide products as among the most affected categories during the period when Medfinder launched [Quartz; Medfinder]. The Quartz feature on Medfinder framed the company as a direct response to that backdrop [Quartz].
A precise TAM for medication-locator services is not published by a major research house in the captured sources, so any sizing here must be treated as analogous rather than confirmed. The closest reference points are the prescription savings and discovery category occupied by GoodRx, which reported revenue in the hundreds of millions annually as a public company, and the broader US retail prescription market, which the IQVIA Institute has sized at roughly 6.7 billion dispensed prescriptions per year. Medfinder's addressable slice is narrower: patients whose prescription cannot be filled at the first pharmacy they try. Industry surveys have repeatedly found that a meaningful share of patients abandon or delay prescriptions because of stock issues, and Medfinder's own marketing cites the figure of "almost 100 hours every year" the average American spends on healthcare navigation, although that statistic is sourced to the company itself rather than to an independent study [Medfinder].
| Sizing reference | Value | Source |
|---|---|---|
| Hours per year average American spends navigating healthcare | ~100 | [Medfinder] (company-cited, unverified) |
| Headcount band, Medfinder | 1-10 employees | [Wellfound] |
| Trustpilot review presence | 21+ pages of reviews indexed | [Trustpilot] |
The analyst takeaway is that the demand-side case is real and topical (shortages of stimulants and GLP-1s are ongoing and well-documented in mainstream press) but the addressable revenue pool for a pure consumer search product is constrained by willingness-to-pay for a one-time fee. The provider channel, by contrast, taps a different budget (clinic operating expense, pharmacy benefit workflow) and is the more interesting expansion vector if it converts.
Regulatory forces cut both ways. Continued DEA quotas on stimulant manufacturing and ongoing GLP-1 supply constraints sustain demand for the product, while any improvement in pharmacy interoperability standards (for example, broader adoption of NCPDP real-time inventory exchanges) could compress the moat that human-verified stock data provides today.
Data Accuracy: YELLOW -- Tailwind narrative supported by Quartz and Medfinder; specific TAM figures are analogous rather than directly confirmed for this segment.
Competitive Landscape
MIXED
Medfinder sits in a narrow gap between prescription-discount marketplaces, pharmacy-owned stock checkers, and informal patient communities, and the structured facts surface one direct named competitor.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Medfinder | Human-verified medication stock locator, consumer + provider | Seed, 1-10 employees | Outsourced live verification of pharmacy inventory | [Medfinder; Wellfound; Quartz] |
| GoodRx | Prescription price comparison and discount marketplace | Public (NASDAQ: GDRX) | Scale, payer relationships, brand recognition | [Medfinder blog references GoodRx as adjacent signal] |
The segment map breaks into three layers. The incumbent layer is dominated by GoodRx, which serves an adjacent need (price discovery and discounts) and which Medfinder's own blog posts treat as a partial substitute for stock checking, noting that a price listing on GoodRx can be an indirect signal that a pharmacy carries a drug [PUBLIC] [Medfinder]. The challenger layer includes other small companies positioning around medication availability, including Med Finder / FasterMedSolutions (a separate entity targeting prescriber and pharmacy workflows for prescription verification, not affiliated with Medfinder) [PUBLIC] [LinkedIn]. The substitute layer is the patient's own labor: phoning pharmacies in sequence, asking a prescriber's office to call around, or relying on subreddit and Facebook group crowdsourcing for shortages of drugs such as Adderall and Ozempic.
Where Medfinder has a defensible edge today is in the operational mechanic itself. A real-time, human-verified stock answer for a specific drug at a specific pharmacy is something neither GoodRx nor a pharmacy chain's own website reliably provides, because no party except the dispensing pharmacy has accurate same-day inventory, and most chains do not expose that data publicly. Medfinder's willingness to pay freelancers to make calls turns a coordination cost into a service [PUBLIC] [Quartz]. The durability of that edge depends on two things: whether call-based verification can be automated over time without losing accuracy, and whether the company can build switching costs on the provider side through workflow integration.
Where Medfinder is most exposed is on the consumer acquisition channel. GoodRx reaches patients at the point of price comparison, which is upstream of the stock question, and any move by GoodRx to add a stock-availability layer would directly threaten the consumer wedge. The company is also exposed in any category where pharmacies themselves publish reliable stock data (some specialty pharmacies and mail-order operators already do this), because the human-verification value evaporates when the source data is already available.
The most plausible 18-month competitive scenario: the winner case is Medfinder establishing the provider-side product as the default referral tool for clinics treating ADHD, weight management, and rare-disease patients, building recurring B2B revenue while the consumer channel remains a marketing funnel. The losing case is GoodRx or a pharmacy benefit manager bolting on a basic stock indicator, compressing consumer willingness to pay for one-time searches before the provider business reaches scale.
Data Accuracy: YELLOW -- GoodRx comparison drawn from Medfinder's own blog references and public market data; other competitors named from raw research.
Opportunity
PUBLIC
If Medfinder executes, the prize is becoming the default routing layer between a written prescription and a pharmacy that can actually fill it.
The headline opportunity. The single largest outcome Medfinder could plausibly become is the medication-availability infrastructure embedded inside e-prescribing and clinic workflows, the layer a clinician or pharmacist queries before sending a script. The cited evidence makes this reachable rather than aspirational for three reasons: drug shortages are a sustained, multi-year condition rather than a transient spike [Quartz]; the company has already built and shipped a provider-facing product with a sales-led motion [Medfinder]; and customer reviews on Trustpilot describe end-to-end coordination with prescribers, indicating the workflow loop is functional today rather than theoretical [Trustpilot]. The same human-verified data layer that powers the consumer search becomes substantially more valuable when sold as a service to clinics that absorb the labor cost of pharmacy phone tag many times per day.
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Provider-network land and expand | Medfinder converts ADHD, weight-management, and rare-disease clinics to a per-seat or per-search SaaS contract | A telehealth chain in stimulants or GLP-1s adopts the provider product as standard workflow | Provider product is already live and demo-gated [Medfinder]; shortage categories overlap with high-volume telehealth verticals [Quartz] |
| Specialty pharmacy partnership | Medfinder becomes the patient-facing locator for limited-distribution drugs that manufacturers fund | A pharma manufacturer with a shortage-prone product sponsors patient access | Company explicitly markets specialty and limited-distribution drug coverage [Medfinder] |
| Verification automation | Human call layer is gradually replaced by API and scraping where available, lifting gross margin | Pharmacy chain or NCPDP standard exposes machine-readable stock | Same operational model, lower cost per search, opens pricing flexibility [Quartz] |
What compounding looks like. The flywheel is data, not network effects in the social sense. Every search Medfinder fulfills generates a time-stamped record of which pharmacy had which drug in stock at what time, in what quantity, and how long the call took to confirm. Aggregated, that dataset is the closest thing to a real-time map of US retail pharmacy inventory for shortage-prone drugs, and it gets more valuable to clinics, pharma manufacturers, and policy researchers as the longitudinal record grows. Trustpilot reviews indicating successful prescriber coordination suggest the loop from search to fill to feedback is already closing on the consumer side [Trustpilot].
The size of the win. A credible public comparable for the consumer wedge is GoodRx (NASDAQ: GDRX), which built a multi-hundred-million-dollar revenue business on prescription price discovery and at peak commanded a market capitalization in the multiple billions. Medfinder's TAM as a pure consumer locator is narrower, but the provider-side opportunity overlaps with health-IT workflow vendors that trade at meaningful enterprise-value multiples on recurring revenue. If the provider scenario plays out and Medfinder reaches even a low-thousand-clinic footprint with five-figure annual contracts, the business resembles a vertical SaaS comparable rather than a consumer marketplace (scenario, not a forecast).
Data Accuracy: YELLOW -- Provider product and consumer reviews confirmed by Medfinder and Trustpilot; comparables and scenarios are analyst framing.
Sources
PUBLIC
[Medfinder] Medfinder | Find Medications In Stock Near You | https://www.medfinder.com
[Medfinder] Medfinder Pricing , Affordable Plans to Locate Medications Nearby | https://www.medfinder.com/pricing
[Medfinder] About Medfinder | https://www.medfinder.com/about
[Medfinder] Medfinder for Providers | https://www.medfinder.com/providers
[Medfinder] Introducing Our New Look: The New Medfinder Brand | https://www.medfinder.com/blog/announcing-our-new-brand
[Medfinder] Adderall IR Shortage 2026: Still Going? Latest Update | https://www.medfinder.com/blog/adderall-ir-shortage-update-what-patients-need-to-know-in-2026
[Medfinder] Medfinder Privacy Policy | https://www.medfinder.com/privacy
[Quartz] This startup helps Americans get Ozempic and Adderall by using overseas freelancers | https://qz.com/ozempic-adderall-medfinder-1851532606
[Pain News Network, August 2024] A Company Will Help You Find a Pharmacy That Has Your Meds | https://www.painnewsnetwork.org/stories/2024/8/29/a-new-company-will-help-you-find-a-pharmacy-that-has-your-medication-in-stock
[Crunchbase] Medfinder - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/medfinder
[PitchBook] Insito Medfinder Company Profile | https://pitchbook.com/profiles/company/545919-85
[Wellfound] Medfinder Careers | https://wellfound.com/company/trymedfinder
[Trustpilot] Medfinder Reviews | https://www.trustpilot.com/review/www.medfinder.com
[LinkedIn] Parth Shah - Medfinder | https://www.linkedin.com/in/parth-jayesh-shah/
[RocketReach] Parth Shah, Medfinder Co-Founder and CTO | https://rocketreach.co/parth-shah-email_95748315
[LinkedIn] Medfinder company page | https://www.linkedin.com/company/trymedfinder
Articles about Medfinder
- Medfinder Wants to Find the Adderall Bottle Sitting on a Pharmacy Shelf Across Town — The Boston startup sells one-time pharmacy searches to patients chasing shortage drugs, and is now pitching prescribers too.